Single User
£3750
PDF
52 pages

Lower Urinary Tract Symptoms Forecast in 12 Major Markets 2018-2028


Lower urinary tract symptoms (LUTS) are a standardised group of symptoms related to problems with the voiding, storage and post-micturition of urine, occurring in both males and females. Differences between sexes regarding the type and frequency of symptoms have been observed. LUTS are a major burden for middle-aged and elderly people, and have a significant influence on health-related quality of life in that group.

This report provides the current prevalent population for Lower Urinary Tract Symptoms across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Japan, China, India, Brazil) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Lower Urinary Tract Symptoms have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main co-morbidities for Crohn’s disease include:

  • Overweight and obesity
  • Arterial hypertension
  • Diabetes mellitus
  • Coronary artery disease
  • Metabolic syndrome (obesity, hypertension, diabetes and dyslipidaemia)
  • Urinary tract infections
  • Neurological disorders
  • Erectile dysfunction in men

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global Lower Urinary Tract Symptoms market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Lower Urinary Tract Symptoms and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Lower Urinary Tract Symptoms’ prevalent population.
  • Identify sub-populations within Lower Urinary Tract Symptoms which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Lower Urinary Tract Symptoms patients.

CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • ADDITIONAL DATA AVAILABLE ON REQUEST
  • TOP-LINE PREVALENCE FOR LOWER URINARY TRACT SYMPTOMS
  • FEATURES OF LOWER URINARY TRACT SYMPTOMS PATIENTS
  • MALE PATIENTS WITH LOWER URINARY TRACT SYMPTOMS
  • FEMALE PATIENTS WITH LOWER URINARY TRACT SYMPTOMS
  • COMORBID CONDITIONS OF LUTS PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN ANALYSIS PUBLICATIONS
  • BLACK SWAN ANALYSIS ONLINE PATIENT-BASED DATABASES
  • PATIENT-BASED OFFERING
  • ONLINE PRICING DATA & PLATFORMS
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Prevalence of LUTS, total (000s)
  • Table 2. Prevalence of LUTS, males (000s)
  • Table 3. Prevalence of LUTS, females (000s)
  • Table 4. Male patients with LUTS by IPSS score (000s)
  • Table 5. Males with LUTS reporting minimal symptoms (000s)
  • Table 6. Males with LUTS reporting post-void UI (000s)
  • Table 7. Males with LUTS reporting urgency (000s)
  • Table 8. Males with LUTS reporting terminal dribble (000s)
  • Table 9. Males with LUTS reporting nocturia >2/night (000s)
  • Table 10. Males with LUTS reporting multiple symptoms (000s)
  • Table 11. Female patients with LUTS by IPSS score (000s)
  • Table 12. Females with LUTS reporting minimal symptoms (000s)
  • Table 13. Females with LUTS reporting urgency (000s)
  • Table 14. Females with LUTS reporting terminal dribble (000s)
  • Table 15. Females with LUTS reporting nocturia >2/night (000s)
  • Table 16. Females with LUTS reporting multiple symptoms (000s)
  • Table 17. Females with LUTS reporting SUI (000s)
  • Table 18. Males with LUTS (reporting minimal symptoms) and bladder/prostate cancer (000s)
  • Table 19. Females with LUTS (reporting minimal symptoms) and bladder cancer (000s)
  • Table 20. Males with LUTS (reporting multiple symptoms) and neurological disorders (000s)
  • Table 21. Females with LUTS (reporting multiple symptoms) and neurological disorders (000s)
  • Table 22. Abbreviations and Acronyms used in the report
  • Table 23. USA Prevalence of LUTS by 5-yr age cohort, males (000s)
  • Table 24. USA Prevalence of LUTS by 5-yr age cohort, females (000s)
  • Table 25. Canada Prevalence of LUTS by 5-yr age cohort, males (000s)
  • Table 26. Canada Prevalence of LUTS by 5-yr age cohort, females (000s)
  • Table 27. France Prevalence of LUTS by 5-yr age cohort, males (000s)
  • Table 28. France Prevalence of LUTS by 5-yr age cohort, females (000s)
  • Table 29. Germany Prevalence of LUTS by 5-yr age cohort, males (000s)
  • Table 30. Germany Prevalence of LUTS by 5-yr age cohort, females (000s)
  • Table 31. Italy Prevalence of LUTS by 5-yr age cohort, males (000s)
  • Table 32. Italy Prevalence of LUTS by 5-yr age cohort, females (000s)
  • Table 33. Spain Prevalence of LUTS by 5-yr age cohort, males (000s)
  • Table 34. Spain Prevalence of LUTS by 5-yr age cohort, females (000s)
  • Table 35. UK Prevalence of LUTS by 5-yr age cohort, males (000s)
  • Table 36. UK Prevalence of LUTS by 5-yr age cohort, females (000s)
  • Table 37. Russia Prevalence of LUTS by 5-yr age cohort, males (000s)
  • Table 38. Russia Prevalence of LUTS by 5-yr age cohort, females (000s)
  • Table 39. Japan Prevalence of LUTS by 5-yr age cohort, males (000s)
  • Table 40. Japan Prevalence of LUTS by 5-yr age cohort, females (000s)
  • Table 41. China Prevalence of LUTS by 5-yr age cohort, males (000s)
  • Table 42. China Prevalence of LUTS by 5-yr age cohort, females (000s)
  • Table 43. India Prevalence of LUTS by 5-yr age cohort, males (000s)
  • Table 44. India Prevalence of LUTS by 5-yr age cohort, females (000s)
  • Table 45. Brazil Prevalence of LUTS by 5-yr age cohort, males (000s)
  • Table 46. Brazil Prevalence of LUTS by 5-yr age cohort, females (000s)
Brazil, Canada, China, France, Germany, India, Italy, Japan, Russian Federation, Spain, United Kingdom, United States of America